Phase II clinical trial of 13-cis-retinoic acid and interferon-α-2a in patients with advanced esophageal carcinoma

Cancer

Volumn 85, Issue 6, 1999, Pages 1213-1217

  Enzinger, Peter C ^b   Ilson, David H ^a   Saltz, Leonard B ^b   Martin, Lisa K ^b   Kelsen, David P ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

13 cis retinoic acid; Adenocarcinoma; Esophageal carcinoma; Interferon

Indexed keywords

ISOTRETINOIN; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHEILITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SCREENING; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0033559225     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990315)85:6<1213::AID-CNCR1>3.0.CO;2-N     Document Type: Article

References (26)

1. Ilson DH, Bains M, Ginsberg RJ, et al. Neoadjuvant therapy of esophageal cancer [review]. Surg Oncol Clin North Amer 1997;6:723-40.
2. Ilson DH, Kelsen DP. 'Systemic therapy in esophageal cancer.' In: Aisner J, Arriagada R, Green M, Martini N, Perry MC, editors. Comprehensive textbook of thoracic oncology. Baltimore: William and Wilkins, 1996:630-49.
3. Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, et al. Fluorouracil and recombinant alfa-2a interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989;7:1769-75.
4. Kelsen D, Lovett D, Wong J, Saltz L, Buckley M, Murray P, et al. Interferon alpha-2a and fluorouracil in the treatment of patients with advanced esophageal cancer. J Clin Oncol 1992;10:269-74.
5. Ilson D, Sirott M, Saltz L, Heelan E, Huang Y, Keresztes R, et al. A phase II trial of interferon alpha-2a, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. Cancer 1995;74:2197-202.
6. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501-5.
7. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
8. Benner SE, Pajak TF, Lippman SM, Earley C, Hong WK. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst 1994;86:140-1.
9. Peck R, Bollag W. Potentiation of retinoic-induced differentiation of HL-60 and U937 cell lines by cytokines. Eur J Cancer 1991;27:53-7.
10. Marth C, Kirchebner P, Daxenbichler G. The role of polyamines in interferon and retinoic acid mediated synergistic antiproliferative action. Cancer Lett 1989;44:55-9.
11. Hemmi H, Breitman TR. Combinations of recombinant human interferons and retinoic acid synergistically induce differentiation of the human promyelocytic leukemia cell line HL-60. Blood 1987;69:501-7.
12. Frey JR, Peck R, Bollag W. Antiproliferative activity of retinoids, interferon alpha and their combination in five human transformed cell lines. Cancer Lett 1991;57:223-7.
13. Lancillotti F, Giandomenico V, Affabris E. Interferon alpha-2b and retinoic acid combined treatment affects proliferation and gene expression of human cervical carcinoma cells. Cancer Res 1995;55:3158-64.
14. Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, et al. 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992;84:235-41.
15. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, et al. 13-cis-retinoic acid plus interferon alpha-2a: highly effective systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992;84:241-5.
16. Lippman SM, Kavanagh IJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, et al. 13-cis-retinoic acid plus interferon alpha-2a in locally advanced squamous cell carcinoma of the cervix. J Natl Cancer Inst 1993;85:499-500.
17. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:1086-91.
18. Wright CD, Mathisen DJ, Wain JC, Grillo HC, Hilgenberg AD, Moncure AC, et al. Evolution of treatment strategies for adenocarcinoma of the esophagus and gastroesophageal junction. Ann Thorac Surg 1994;58:1574-9.
19. Ajani JA, Roth JA, Ryan MB, Putnam JB, Pazdur R, Levin B, et al. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 1993;11: 22-8.
20. Miller AB, Hoogstratten B, Staquet M, Winkler A. Reporting of results of cancer treatment. Cancer 1981;47:207-14.
21. Hallum AV, Alberts DS, Lippman SM, Inclan L, Shamdas GJ, Childers JM, et al. Phase II study of 13-cis-retinoic acid plus interferon alpha-2a in heavily pretreated squamous carcinoma of the cervix. Gynecol Oncol 1995;56:382-6.
22. Voravud N, Lippman SM, Weber RS, Rodriguez GI, Yee D, Dimery IW, et al. Phase II trial of 13-cis-retinoic acid plus interferon in recurrent head and neck cancer. Invest New Drugs 1993;11:57-60.
23. Arnold A, Ayoub J, Douglas L, Hoogendoorn P, Skingley L, Gelmon K, et al. Phase II trial of 13-cis-retinoic acid plus interferon alpha in non-small-cell lung cancer. J Natl Cancer Inst 1994;86:306-9.
24. Toma S, Palumbo R, Vincenti M, Aitini E, Paganini G, Pronzato P, et al. Efficacy of recombinant alpha-interferon 2a and 13-cis-retinoic acid in the treatment of squamous cell carcinoma. Ann Oncol 1994;5:463-5.
25. Slabber CF, Falkson G, Burger W, Schoeman L. 13-cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: a phase II trial. Invest New Drugs 1996; 14:391-4.
26. Kok TC, van der Gaast A, Splinter TAW. 13-cis-retinoic acid and alpha interferon in advanced squamous cell cancer of the oesophagus, [letter]. Eur J Cancer 1997;33:166-7.